Shanghai, China, March 24, 2026 – Asieris Pharmaceuticals (688176.SH) today announced a strategic partnership with Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (SPH Kyuan Trade), a subsidiary of Shanghai Pharma. The two companies will engage in in-depth strategic cooperation on the import and distribution of Cevira® in China, leveraging their respective strengths to jointly accelerate the commercialization of Cevira® and benefit patients in China at an early date.
In March of this year, Asieris announced that its core product Cevira® received the Drug Registration Certificate from the National Medical Products Administration (NMPA) for its commercial launch. The product is indicated for the treatment of patients aged 18 and older with histologically confirmed cervical high-grade squamous intraepithelial lesions (HSIL), specifically Cervical Intraepithelial Neoplasia Grade 2, CIN2. As the world’s first non-surgical, non-invasive product for treating precancerous cervical lesions1, Cevira® is poised to reshape a treatment landscape long dominated by surgical and other invasive or minimally invasive interventions. It will enable a shift from invasive surgical interventions toward a non-invasive treatment approach, offering a breakthrough solution to current clinical challenges.
Dr. Kevin Pan, Founder, Chairman and CEO of Asieris Pharmaceuticals, stated, “We are very pleased to enter into this strategic partnership with SPH Kyuan Trade. With their deep expertise in pharmaceutical import and channel distribution, SPH Kyuan Trade will strongly support the widespread clinical application of Cevira®, bringing this innovative therapy to patients more quickly. We believe this collaboration represents a significant opportunity for two industry leaders to join forces and create shared value. Together, we will work to bring this non-invasive treatment for precancerous cervical lesions to more patients in China, contributing to the ‘Healthy China 2030’ initiative.”
Chu Chenxi, Chairman and General Manager of SPH Kyuan Trade, said, “Asieris’ dedication and breakthrough innovations in the field align closely with the principles we have long championed. We feel a profound sense of responsibility in jointly advancing this promising innovative therapy to serve patients in China more quickly. SPH Kyuan Trade will fully leverage its comprehensive strengths in import access, omni-channel distribution, and policy coordination, and is committed to providing Asieris with precisely tailored service solutions. We firmly support innovative companies like Asieris, and look forward to deepening our collaboration to jointly bring innovative achievements in this field to more patients, working hand in hand to fulfill the mission of ‘Healthy China 2030’ initiative.”
Attending the signing ceremony were Dr. Kevin Pan, Founder, Chairman and CEO of Asieris; Helen Xu, Chief Commercial Officer of Asieris; Chu Chenxi, Chairman and General Manager of SPH Kyuan Trade; Zhang Dejun, Deputy General Manager of SPH Kyuan Trade; Zhang Lin, General Manager of the Procurement Business Unit and Clinical Business Unit of SPH Kyuan Trade.
[1] Insight Database
About SPH Kyuan Trade
Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. is a core pharmaceutical import and distribution enterprise under Shanghai Pharma Holdings (a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., a Fortune Global 500 company for many years). Established in 2009 within the Beijing Tianzhu Free Trade Zone, it is a large-scale, diversified, comprehensive service-oriented pharmaceutical company integrating import bonded services, pharmaceutical distribution, vaccine services, digital marketing, market access, and supply chain extension services, with a business coverage across China.
Adhering to the “Service-oriented” corporate culture, its distribution network spans 31 provinces, municipalities, and autonomous regions across China, covering over 1,000 distributors, more than 2,500 district and county-level centers for disease control and prevention, and over 100,000 retail pharmacies. Leveraging its highest customs credit rating and multiple customs clearance facilitation policies, the company provides one-stop import solutions for numerous renowned global pharmaceutical companies, with over 230 specifications of imported pharmaceuticals and vaccines.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and women’s health. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus.
Through proprietary R&D and strategic collaborations, the company is committed to developing first-in-class drugs and other innovative technologies and products that address significant unmet medical needs, building a robust portfolio spanning from disease diagnosis to treatment within its focused therapeutic areas. Driven by patient needs, we are comprehensively advancing Commercialization 2.0 to improve the accessibility and affordability of innovative products, thereby benefiting more patients in China and globally.